Kewaunee Scientific (US:KEQU)2021-03-12 16:55Sales Performance - Sales for the quarter were $33,339,000, a 2.6% decrease from $34,225,000 in the comparable period of the prior year[64] - Domestic sales for the quarter were $25,066,000, down 6.1% from $26,699,000 in the comparable period of the prior year[64] - International sales for the quarter were $8,273,000, up 9.9% from $7,526,000 in the comparable period of the prior year[64] Financial Metrics - The gross profit margin for the three months ended January 31, 2021 was 17.0% of sales, compared to 15.4% in the comparable quarter of the prior year[67] - Operating expenses for the three months ended January 31, 2021 were $6,030,000, or 18.1% of sales, down from $7,350,000, or 21.5% in the comparable period of the prior year[68] - Net earnings were $81,000, or $0.03 per diluted share, for the three months ended January 31, 2021, compared to a net loss of $1,918,000, or $0.70 per diluted share, in the prior year period[75] Order Backlog and Working Capital - The Company's order backlog was $103 million at January 31, 2021, compared to $93 million at January 31, 2020[66] - The Company had working capital of $28,510,000 at January 31, 2021, compared to $27,171,000 at April 30, 2020[77] Future Outlook - The Company expects its performance to continue to improve based on its reduced cost structure and investments in modernizing operations[81] - The Company continues to actively monitor the COVID-19 pandemic and its potential impact on operations and financial condition[80]